BRCA-1の移植前遺伝子検査とリスク軽減手術は,40歳より35歳で費用対効果が高くなります
Kiley Hunkler1, David Boedeker1, Kelby Bulles2
1Walter Reed National Military Medical Center, Bethesda, MD.
Fertility and sterility
|February 22, 2026
まとめ
BRCA1変異媒介者の場合,35歳の時にプリインプランテーション検査による体外受精は,40歳まで介入を延期するよりも費用対効果が高くなります. この戦略は生児の数を増やし,卵巣がんの発生率と死亡率を低下させます.
科学分野:
- 生殖医学と腫瘍学.
- 健康経済学と意思決定分析.
背景:
- BRCA1変異のキャリアは,卵巣がんや乳がんのリスクが高くなります.
- 予防的なサルピングオオフォレクトミー手術は,リスク軽減の重要な戦略です.
- 生殖の欲求とがんリスク管理は,複雑な決断を迫るものです.
研究 の 目的:
- BRCA1変異媒介者の早期 (35歳) と遅延 (40歳) の介入の費用対効果を比較する.
- 介入には,単一性疾患に対する植入前の遺伝子検査 (PGT) による体外受精 (IVF) と,リスクを軽減する双方のサルピング・オオフォレクトミー (RRBSO) が含まれる.
主な方法:
- マルコフ数学モデルを用いて費用対効果の分析を行った.
- 確率,コスト,ユーティリティに関するデータは,既存の文献から得られた.
- 主なアウトカムは,品質調整寿命年 (QALY) につき100,000ドルの支払意向 (WTP) の値に対して,インクリメンタル費用対効果比 (ICER) によって測定された費用対効果でした.
主要な成果:
- 35歳の介入は,ICER -153.3の40歳への遅延よりも絶対的な優位性を示しました.
- 35歳までの戦略により,生児が950人増加し,卵巣がんが726人減少し,BRCA1キャリア1万人に死亡者が705人減少した.
- 40歳まで介入を遅らせると,費用が370万ドル増加し,QALYが24,379人減少した;確率的感度分析は,WTPの値を超えて35歳コホートの優位性を$200,000まで確認した.
結論:
- 35歳でモノジェニック疾患に対するPGTによるIVFを実施することは,BRCA1変異媒介者の場合,40歳まで延期するよりも費用対効果が高くなります.
- この戦略は,生殖の成果を向上させ,卵巣がんの負担を大幅に軽減します.
- 多分野チームとの共同意思決定は,BRCA1キャリアのカウンセリングに不可欠です.
関連する概念動画
Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


